---
title: "Transdiagnostic NIMETOX metabolic signatures in major depressive disorder and schizophrenia"
id: "medrxiv-6-transdiagnostic-metabolic-architecture-across-major-depressive-disorder-and"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-6-transdiagnostic-metabolic-architecture-across-major-depressive-disorder-and"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.28.26364141v1?rss=1"
published_at: "2026-09-29T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Transdiagnostic NIMETOX metabolic signatures in major depressive disorder and schizophrenia
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-6-transdiagnostic-metabolic-architecture-across-major-depressive-disorder-and
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.28.26364141v1?rss=1)
- **Published At:** 2026-09-29T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study applies a **NIMETOX** (neuroimmune metabolic oxidative) systems-biology framework to test shared and distinct serum metabolic signatures across **major depressive disorder (MDD)** and **schizophrenia (SCZ)**. - Sample comprised 89 participants: 26 healthy controls (HC), 34 with MDD, and 29 with SCZ. Untargeted serum metabolomics detected 1,419 metabolites. - From the dataset the authors selected 38 marker metabolites and organized them into 11 metabolic modules for downstream analysis. - Compared with HC, both MDD and SCZ showed reduced **mitochondrial lipid bioenergetics** and decreased **metabolic resilience**, alongside increased **sphingolipid stress signaling**, **oxidative lipid damage**, and **renin–angiotensin–aldosterone system (RAAS) stress**. - Progressive changes in polyunsaturated fatty acid (PUFA) membrane remodelling were observed, increasing from HC to SCZ to MDD; antioxidant levels were selectively lower in MDD only. - An integrated orthogonal partial least squares discriminant analysis (OPLS-DA) separated HC from combined MDD+SCZ with a cross-validated area under the curve (AUC) of 0.946. - Across dimensional (continuous) clinical models, modules reflecting mitochondrial lipid bioenergetics, PUFA remodelling, sphingolipid stress, oxidative lipid damage, and metabolic resilience explained substantial variance in mood symptoms, psychotic symptoms (positive and negative), resilience, and suicidal behaviors. - A terpenoid exposure biotransformation module was strongly associated with psychosis and suicidal behaviors. - The authors conclude MDD and SCZ share an interconnected **NIMETOX metabolic architecture**, while dimensional clinical features show partly distinct psychosocial–metabolic configurations, offering a framework for future stratification and biomarker validation. - Ethical approval was obtained (Ethics Committee of the University of Electronic Science and Technology of China, IRB No. 30850). Data are available on reasonable request. The work was supported by the National Nature Science Foundation of China (W2633246).
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=8Qr2NIuiOk8v4risDib9wH8Gam6dfe6kKzdJPMcwU6o-1790749307.8564553-1.2.1.1-r9x7yaP7PEIup9PQBKTyGUbDqUapv2MkSF5qD314Ptm3zety1gR4guQwh4UJqx2n) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.28.26364141v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Transdiagnostic metabolic architecture across major depressive disorder and schizophrenia: a NIMETOX systems-biology approach Yueyang Luo, Hongzhou Wu, Chenghui Yang, Tangcong Chen, Abbas F Almulla, Yingqian Zhang, Michael Maes doi: https://doi.org/10.64898/2026.09.28.26364141 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Yueyang Luo 1 1.International NIMETOX Center, Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Yueyang%2BLuo%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Luo%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AYueyang%2BLuo%2B) Hongzhou Wu 2 1. International NIMETOX Center, Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China. 2. The Clinical Hospital of Chengdu B; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hongzhou%2BWu%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wu%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHongzhou%2BWu%2B) Chenghui Yang 3 1. International NIMETOX Center, Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Chenghui%2BYang%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Yang%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChenghui%2BYang%2B) Tangcong Chen 3 1. International NIMETOX Center, Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tangcong%2BChen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Chen%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATangcong%2BChen%2B) Abbas F Almulla 4 1. International NIMETOX Center, Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China. 3. Medical Laboratory Technology Depar; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Abbas%2BF%2BAlmulla%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Almulla%20AF&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAbbas%2BF%2BAlmulla%2B) Yingqian Zhang 3 1. International NIMETOX Center, Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Yingqian%2BZhang%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Zhang%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AYingqian%2BZhang%2B) Michael Maes 5 1. International NIMETOX Center, Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China. 4. Department of Psychiatry, Faculty o * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Michael%2BMaes%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Maes%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMichael%2BMaes%2B) * For correspondence: michaelmaes@uestc.edu.cn * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.28.26364141v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1310283/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.28.26364141v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1310283/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.28.26364141v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1310283/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.09.28.26364141v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1310283/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.28.26364141v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1310283/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.28.26364141v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1310283/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Major depressive disorder (MDD) is conceptualised within a neuroimmune metabolic oxidative (NIMETOX) framework. From a systems-biology perspective, related metabolic oxidative disturbances may extend across diagnostic boundaries, including schizophrenia (SCZ), but their relationships with childhood adversity and dimensional psychopathology remain unclear. Objectives: To characterize shared and divergent serum metabolic signatures across MDD and SCZ and their associations with childhood adversity, resilience, and dimensional clinical phenotypes. Methods: We studied 89 participants (26 HC, 34 MDD, 29 SCZ). Untargeted serum metabolomics yielded 1,419 metabolites, of which 38 selected markers were integrated into 11 metabolic modules. Group comparisons, nested cross-validated OPLS-DA, and multiple regression analyses were performed. Results: Compared with HC, MDD and SCZ exhibited reduced mitochondrial lipid bioenergetics and metabolic resilience and increased sphingolipid stress signalling, oxidative lipid damage, and renin angiotensin aldosterone system stress. PUFA membrane remodelling increased progressively from HC to SCZ to MDD, whereas antioxidants were selectively reduced in MDD. An integrated OPLS-DA discriminated HC from MDD+SCZ (cross-validated AUC=0.946). Across dimensional models, mitochondrial lipid bioenergetics, PUFA remodelling, sphingolipid stress, oxidative lipid damage, and metabolic resilience explained substantial variance in mood, positive and negative psychotic symptoms, resilience, and suicidal behaviors. A terpenoid exposure biotransformation module was strongly associated with psychosis and suicidal behaviors. Conclusion: MDD and SCZ share an interconnected NIMETOX metabolic architecture while clinical dimensions show partly distinct psychosocial metabolic configurations. These findings support a transdiagnostic NIMETOX systems biology model linking NIMETOX dysfunction with dimensional psychopathology and provide a framework for future stratification and biomarker validation. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was approved by the Ethics Committee of the University of Electronic Science and Technology of China (IRB No. 30850). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present study are available upon reasonable request to the authors ## Funder Information Declared National Nature Science Foundation of China, W2633246 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.28.26364141v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.27.26364131v1 "APOE ε4 Carrier Status and Cognitive Decline in Mild-to-Moderate Alzheimer's Disease: A Linear Mixed-Effects Analysis of the Placebo Arm of EXPEDITION 1")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.28.26364198v1 "DNA Methylation of Neurodevelopmental, Stress-Response, Reward, and Opioid Pathway Genes: Sex Differences in Infants with Neonatal Opioid Exposure") Posted September 29, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.28.26364141v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/29/2026.09.28.26364141.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.28.26364141v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.09.28.26364141v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/29/2026.09.28.26364141.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Transdiagnostic metabolic architecture across major depressive disorder and schizophrenia: a NIMETOX systems-biology approach Yueyang Luo, Hongzhou Wu, Chenghui Yang, Tangcong Chen, Abbas F Almulla, Yingqian Zhang, Michael Maes medRxiv 2026.09.28.26364141; doi: https://doi.org/10.64898/2026.09.28.26364141 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.28.26364141v1%26text%3DTransdiagnostic%2520metabolic%2520architecture%2520across%2520major%2520depressive%2520disorder%2520and%2520schizophrenia%253A%2520a%2520NIMETOX%2520systems-biology%2520approach "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.28.26364141v1%26t%3DTransdiagnostic%2520metabolic%2520architecture%2520across%2520major%2520depressive%2520disorder%2520and%2520schizophrenia%253A%2520a%2520NIMETOX%2520systems-biology%2520approach "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.28.26364141v1%26title%3DTransdiagnostic%2520metabolic%2520architecture%2520across%2520major%2520depressive%2520disorder%2520and%2520schizophrenia%253A%2520a%2520NIMETOX%2520systems-biology%2520approach%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.28.26364141v1%26title%3DTransdiagnostic%2520metabolic%2520architecture%2520across%2520major%2520depressive%2520disorder%2520and%2520schizophrenia%253A%2520a%2520NIMETOX%2520systems-biology%2520approach "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.28.26364141) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.09.28.26364141v1&count=horizontal&via=&text=Transdiagnostic%20metabolic%20architecture%20across%20major%20depressive%20disorder%20and%20schizophrenia%3A%20a%20NIMETOX%20systems-biology%20approach&counturl=www.medrxiv.org/content/10.64898/2026.09.28.26364141v1 "Tweet This") ## Subject Area * [Psychiatry and Clinical Psychology ](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (622) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (909) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (339) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4862) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (482) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (420) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (656) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1639) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16029) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (34) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1214) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7107) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (735) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1071) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5099) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1441) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1786) * [Hematology](https://www.medrxiv.org/collection/hematology) (588) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1351) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16342) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1181) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (675) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (728) * [Neurology](https://www.medrxiv.org/collection/neurology) (7354) * [Nursing](https://www.medrxiv.org/collection/nursing) (370) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1096) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1253) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1008) * [Oncology](https://www.medrxiv.org/collection/oncology) (3645) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1063) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (399) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (459) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (480) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (140) * [Pathology](https://www.medrxiv.org/collection/pathology) (710) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1816) * [Pharmacology and Therapeutics](https://w
## Related Clinical Research

- [Multi-organ imaging genetics: integrating brain–body links for neurological disease](https://medichelpline.com/clinical-feed/nature-reviews-neurology-0-multi-organ-imaging-genetics-towards-an-integrated-view-of-brain-body-and-brain.md)
- [NeuroMark dFNC: Transferable Templates for Subject-Specific Dynamic Connectivity](https://medichelpline.com/clinical-feed/biorxiv-6-neuromark-dfnc-transferable-dynamic-state-templates-for-subject-specific-and.md)
- [Safety of Stroboscopic Light Stimulation: Observational Evidence and Guidelines](https://medichelpline.com/clinical-feed/plos-one-23-stroboscopic-light-stimulation-safety-within-and-beyond-laboratory-settings.md)
- [High-definition 0.75 Hz so-tDCS for older adults with SCD and sleep disturbance: randomized trial](https://medichelpline.com/clinical-feed/plos-one-13-personalized-assessment-of-high-definition-slow-oscillatory-transcranial-direct.md)
- [DataPlex: A 700-Subject Labeled MRI Dataset for Lateral Ventricle Choroid Plexus Segmentation](https://medichelpline.com/clinical-feed/biorxiv-15-a-large-comprehensive-labeled-mri-dataset-of-the-human-lateral-ventricle.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.